Are compounded GLP-1s banned after the shortage ended?

Not entirely. The broad shortage-based pathway for mass-market copies of semaglutide and tirzepatide has ended, but a narrow, patient-specific kind of compounding can still be legal when a prescriber documents a real medical reason.

Is compounded semaglutide still legal in 2026?

It depends on the facts -- the prescription, the pharmacy, the formula, and whether there's a documented patient-specific reason. Routine, mass-market copies should not be treated the way they were during the shortage.

Is compounded tirzepatide still legal in 2026?

Same framework as semaglutide. The shortage-based window closed in 2025, and any ongoing compounding needs a genuine, documented, individual reason -- not a marketing claim.

Can pharmacies still compound GLP-1s if they add B12?

Adding B12 does not automatically make a copy legal. The FDA has said a semaglutide-plus-B12 product can still count as essentially a copy depending on the dose and route. Ask what specific medical difference was documented for you.

What is 503A compounding?

503A refers to a state-licensed pharmacy (or physician) compounding a medication for one named patient based on a prescription.

What is 503B compounding?

503B refers to larger outsourcing facilities that make compounded drugs in batches under stricter federal rules, with tight limits on using raw drug powder unless the drug is in shortage or on a special approved-ingredient list.

Are compounded GLP-1s FDA-approved?

No. The FDA does not review compounded drugs for safety, effectiveness, or quality before they're sold, and they are not the same as FDA-approved generics.

What should I do if my refill was canceled?

Don't buy from an unverified seller. Get your prescription records, ask your provider why it stopped, ask whether a legal option fits you, and compare FDA-approved programs before you spend anything.

Are semaglutide sodium and semaglutide acetate safe?

The FDA says these salt forms are different active ingredients than the approved drug and that it is aware of no lawful basis for using them in compounding. Treat them as a red flag.

Can I just buy retatrutide or cagrilintide online instead?

No. The FDA says these cannot legally be compounded and have not been found safe or effective for any condition. Don't buy them from research-peptide sellers.

Why are some providers still advertising compounded GLP-1s?

Some lean on patient-specific compounding arguments, different formulas, or outdated marketing. Verify the prescriber, the pharmacy, and the legal basis before trusting any of it.

What's the best legal option now that compounded access has changed?

For most people, the most straightforward legal path is an FDA-approved medication prescribed by a licensed clinician -- but your eligibility, cost, coverage, diagnosis, and medical history decide what's right for you.

GLP-1 Compounding Rules After Shortage Ends: What’s Still Legal in 2026?

The cheap-copies door has mostly closed — but “mostly” is doing a lot of work in that sentence.

By The RX Index Editorial TeamLast verified: June 9, 2026Disclosure

What this page is: a plain-English explainer of the current FDA rules, plus a checklist for your next step. What it is not: legal advice, medical advice, or a substitute for a licensed clinician.

If you’re trying to make sense of the GLP-1 compounding rules after the shortage ends, here’s the bottom line up front: now that the FDA has declared the semaglutide and tirzepatide shortages over, pharmacies can no longer make cheap, mass-market copies of these drugs the way they did in 2023 and 2024. That door has mostly closed.

But “mostly” is doing a lot of work. A narrow, one-person kind of compounding can still be legal. “They added B12, so it’s fine” is a myth the FDA has shot down by name. And some of the “alternatives” floating around online right now are exactly the ones the FDA is warning people to avoid. If your refill just got canceled, take a breath — don’t panic-buy from a site you found yesterday.

The short version

Your question	The honest answer
“Did the old shortage pathway for compounded semaglutide and tirzepatide end?”	Yes. It ended in 2025.
“Is all compounding banned now?”	No. A narrow, patient-specific kind can still be legal.
“Does "we added B12" make a copy legal?”	No -- not by itself. The FDA has said so directly.
“Are compounded GLP-1s FDA-approved?”	No. The FDA does not review them for safety, effectiveness, or quality before they're sold.
“My refill stopped -- what do I do?”	Don't buy from a random site. Verify the source, call your prescriber, and compare legal options below.

Compounding just means a pharmacy mixing a custom medication for a patient instead of dispensing a mass-produced, FDA-approved one. During the shortage, that’s how a huge cash-pay market grew — often around $150–$300 a month, far below brand-name list prices. The rules for doing it have now changed in a big way.

Check my situation — free 60-second quiz →

Your medication, where you’ve been getting it, your insurance, and your state — we’ll tell you which situation you’re in and what to ask your prescriber next.

What people are actually saying right now

"My pharmacy stopped my refill and won't say why."
"What does 'the shortage is over' even mean for me?"
"Insurance said no -- now what?"
"I feel like the rug got pulled out from under me."

Common sentiments we see expressed online — not medical advice, and not proof of typical results. If any sound like you, you’re in the right place.

What are the GLP-1 compounding rules after the shortage ends?

The core rule: once the FDA declared the semaglutide and tirzepatide shortages resolved, the shortage-based pathway that let pharmacies make copies of these drugs on a large scale went away. Compounded versions are not FDA-approved, and routine copying of an available brand drug is now restricted. A narrow, patient-specific compound can still be legal when a prescriber documents a real medical reason it must differ from the approved drug.

During a shortage, the law lets compounders step in and make copies of a drug patients can’t otherwise get. That permission is tied to one thing — the shortage. Once it ends and the drug is available again, the FDA has reminded compounders of the legal limits on copying FDA-approved drugs.

The phrase to know: “essentially a copy”

A compounded drug is “essentially a copy” when it’s basically the same as a commercially available, FDA-approved product — same active ingredient, same strength, same way of taking it. Now that semaglutide and tirzepatide are widely available, pharmacies generally can’t keep making essentially-a-copy versions of them in volume. The better question is: “Is this product essentially a copy of the brand drug — and if so, is there a documented, patient-specific reason it’s being made?”

A straight admission, because you deserve one: we can’t hand you a loophole to keep buying cheap compounded semaglutide like it’s 2024. For most people, that legal door has closed, and any seller promising otherwise should make you suspicious — not relieved. The part that actually matters: you have real, legal options that now cost far less than brand-name drugs used to, and a clear path to keep your progress going. We’ll get you there below.

Take the free “Find My GLP-1 Path” quiz →

Tell us your medication, insurance status, and whether your refill is still active. Get a plain-English next-step checklist to bring to your doctor.

When exactly did the compounding rules change?

The FDA ended the shortage-based compounding window for tirzepatide first, in early 2025, and for semaglutide a few months later. Compounders sued to stop the changes, but federal courts sided with the FDA both times. Here are the dates that actually control.

Tirzepatide (Mounjaro, Zepbound)

FDA took tirzepatide off the shortage list in October 2024 and confirmed that decision in December. After a court backed the FDA on March 5, 2025, pharmacies had to stop making copies; larger outsourcing facilities had until March 19, 2025 to wind down.

Semaglutide (Ozempic, Wegovy)

The FDA declared the semaglutide shortage over on February 21, 2025. After a court backed the FDA again on April 24, 2025, pharmacies had to stop; outsourcing facilities had until May 22, 2025.

Then it tightened further

Through late 2025 and into 2026, the FDA ramped up enforcement. In March 2026 it sent 30 warning letters to telehealth companies over how they marketed compounded GLP-1s. On April 30, 2026, the FDA proposed a rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list — meaning outsourcing facilities could lose any remaining pathway permanently.

Where the rules stand now

Compounding path	Semaglutide	Tirzepatide	What changed
Routine copies of the brand drug, made in volume	Restricted	Restricted	Pharmacy windows closed after court rulings (Apr 24, 2025 for semaglutide; Mar 5, 2025 for tirzepatide); outsourcing facilities closed May 22 / Mar 19, 2025
Large-batch making from raw drug powder (503B outsourcing facilities)	Restricted -- proposed permanent ban	Restricted (same)	Proposed bulk-list exclusion, Apr 30, 2026 (not yet final)
A pharmacy filling 4 or fewer copy-style prescriptions in a month	FDA says it does not currently plan to act on these	Same	FDA clarification, Apr 1, 2026
A true one-person prescription with a documented medical reason it must differ from the brand	Can still be legal, case by case	Can still be legal, case by case	Ongoing (FDA's "significant difference" rule)

Why people are still so confused. Three reasons. First, old provider pages and forum posts from 2023–2024 are still online. Second, some sellers quietly swapped “shortage” language for “patient-specific” language without much else changing. Third, a national shortage ending doesn’t mean every pharmacy instantly has every dose.

What “resolved” does NOT mean. “Resolved” means the FDA decided the national supply can meet demand again. It does not mean your corner pharmacy always stocks your exact dose, and it does not mean compounding pharmacies broke the law just by existing. It simply means the special shortage permission that powered the compounding boom has expired.

Is compounded tirzepatide still legal after the shortage?

Compounded tirzepatide faces the same rules as semaglutide. The shortage-based window closed in 2025, so routine copies of Zepbound or Mounjaro are no longer the easy, legal pathway they were. A one-person prescription with a documented medical reason may still be possible, but it’s narrow — and not FDA-approved.

Tirzepatide users actually felt the change first, because the FDA ended tirzepatide’s shortage status before semaglutide’s. If your tirzepatide refill stopped sometime in 2025, that timing is almost certainly why.

The trap to avoid: some pharmacies now add an ingredient (like B12) or tweak the dose and market it as a “personalized” tirzepatide that sidesteps the rules. That theory is contested, and the FDA has signaled it’s skeptical of it. We break it down in detail below.

What’s the difference between 503A and 503B compounding?

Type	Who they are	How they work	Status for GLP-1s now
503A	State-licensed compounding pharmacies	Mixes custom medication for one named patient, based on a prescription. One prescription at a time.	Still possible in narrow, patient-specific cases with a documented medical reason
503B	Larger outsourcing facilities	Makes compounded drugs in larger batches, often without a specific patient prescription. Stricter federal oversight.	Restricted for semaglutide and tirzepatide; proposed for permanent exclusion from the bulk-compounding list

Why you should care: “compounded by a licensed pharmacy” sounds reassuring, but it’s not enough detail. You want to know which pharmacy, whether it’s 503A or 503B, and what reason was documented for compounding it for you specifically. A trustworthy provider can answer those questions without dodging.

Does adding B12 or changing the dose make a compounded GLP-1 legal?

Not on its own. The FDA has specifically said that combining semaglutide with another ingredient like vitamin B12 can still count as “essentially a copy” of the approved drug, depending on the dose and how it’s taken. A change only helps if a prescriber documents a real, significant medical reason for you as an individual.

The B12 myth

Don’t read “now with B12!” as “now it’s legal and safe.” Read it as a claim to verify. If a provider is leaning on a B12 combo, ask: what specific, documented medical reason makes this version necessary for me? If they can’t answer, that’s your answer.

Custom dosing

Adjusting a dose can be genuinely useful for some patients. But marketing a “custom dose” as a blanket workaround to keep selling copies is a different thing. The medical reason has to be specific to you and written down by your prescriber — not a marketing line applied to everyone.

Drops, tablets, lozenges, and “sublingual” versions

A different form — say, under-the-tongue drops instead of an injection — isn’t automatically legal, safe, or proven. It definitely doesn’t carry the same testing as an FDA-approved medicine. Treat any oral or sublingual compounded GLP-1 as something to run past a licensed clinician or pharmacist first.

We can’t tell you whether one specific compounded prescription is legal for your exact situation. That depends on your prescriber’s documentation, the pharmacy, the formula, your state, and the facts of your case. But that limit is exactly why the questions above matter — if a provider can’t clearly answer them, you’ve learned something important before you put anything in your body.

Why did the FDA crack down — and what red flags should stop you cold?

The FDA found no clinical need for outsourcing facilities to make these drugs from bulk powder once the shortage ended. Cost or insurance access isn’t the kind of “clinical need” that justifies compounding. But the bigger story for you as a patient is safety. The FDA has flagged unapproved salt forms, illegal research-only peptides, fake pharmacy labels, dosing-error injuries, and outright counterfeits in the compounded GLP-1 market.

In March 2026, the FDA sent 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1s — the second batch in a six-month stretch where the agency sent thousands of letters to drug and telehealth firms, more than in the entire previous decade. Main problems: implying a compounded product is the same as an FDA-approved drug, and hiding who actually compounded it by slapping the telehealth company’s own brand on it.

Red flags the FDA has warned about

What you see	Why it’s a problem
"Semaglutide sodium" or "semaglutide acetate"	The FDA says these salt forms are different active ingredients than the approved drug, and it knows of no lawful basis for using them in compounding.
"Retatrutide" or "cagrilintide"	The FDA says these cannot legally be compounded and have not been found safe or effective for any condition.
"For research use only" / "not for human consumption" -- but sold with dosing instructions	The FDA warns these are unapproved products of unknown quality and tells consumers not to buy them for personal use.
No pharmacy named, or one you can't verify	The FDA has found fake labels listing pharmacies that don't exist -- and real pharmacies' names on products they never made.
"Generic Ozempic," "same as Wegovy," "FDA-approved compound"	Not true. Compounded drugs are not FDA-approved and are not generics. This is exactly what those 30 warning letters were about.
No prescription required	A major legal and safety red flag. Walk away.
A price that seems too good to be true	Can signal counterfeit ingredients, hidden fees, or unsafe sourcing.

If you spot any of these, stop and talk to a licensed clinician or pharmacist before using the product. You can also report a bad product or a reaction to the FDA’s MedWatch program.

What are your legal options now — and what do they actually cost?

Your realistic legal options are FDA-approved medications, and the good news is they cost far less than they used to. As of mid-2026: the oral Wegovy pill runs about $149–$299 a month, Zepbound vials through the maker’s own program run $299–$449, Wegovy injections start at $199 for the first two months, and a new pill called Foundayo joined in April 2026. None of these is the $1,000-plus nightmare you may be picturing.

Option	What it is	Indicative cash price	Worth knowing
Wegovy pill (oral semaglutide)	FDA-approved	$149-$299/mo by dose (NovoCare)	Launched Jan 2026
Zepbound vials via LillyDirect	FDA-approved tirzepatide	$299 (2.5 mg) / $399 (5 mg) / $449 (maintenance)	Self-pay; refill within 45 days to hold maintenance price
Wegovy via NovoCare	FDA-approved semaglutide	$199/mo first two fills (0.25 & 0.5 mg) through June 30, 2026, then $349; high dose 7.2 mg is $399	Eligibility applies
Foundayo (orforglipron)	FDA-approved pill (approved Apr 1, 2026)	Self-pay $149-$349/mo by dose (LillyDirect)	Medicare GLP-1 Bridge starts July 1, 2026 at ~$50/mo for eligible members
A one-person 503A compound (real medical need)	Personalized, prescriber-documented	Varies	Legal only case by case; not FDA-approved

Prices change often — re-check before you commit. Last verified June 9, 2026.

Stop comparing $149 to $1,300

A lot of people freeze because they’re comparing their old compounded price to the retail list price of a brand drug ($1,000–$1,350). That’s not the real comparison anymore. The honest comparison is your old price versus today’s cash-pay programs — and once you put $199–$449 on the table next to $1,300, the decision gets a lot less scary. Yes, it may cost more than compounded did. But it’s real, it’s legal, and it’s nothing like the sticker shock the headlines suggest.

Where a telehealth provider fits

If you’d rather not coordinate prescriptions and pricing yourself, an online provider can handle the visit, the prescription, and the insurance legwork for you. For an FDA-approved route, Ro connects eligible patients to FDA-approved GLP-1s — including the Wegovy pill and pen, Zepbound, Ozempic, and the new Foundayo — and runs a free insurance coverage checker that tells you what your plan might cover before you spend a dime.

One thing to be clear about: the Ro Body membership is $39 the first month, then $149/month (or as low as $74/month prepaid annually). That fee does not include the medication — billed separately at manufacturer cash prices, no markup. And Ro isn’t available if you have Medicare, Medicaid, or TRICARE. If that’s you, go straight to LillyDirect or NovoCare, or take our quiz for a route that fits.

Ro is NOT the cheapest way to get an FDA-approved GLP-1. If rock-bottom price is your only goal and you already have a prescriber, buying direct from the manufacturer skips the membership fee. But Ro’s insurance concierge fights prior authorizations and handles the paperwork — which can save people who’d otherwise pay full cash price hundreds of dollars a month, without gambling on a gray-market seller.

Check FDA-approved GLP-1 coverage — free with Ro’s Insurance Checker →

A few questions, no commitment. See where you stand on Wegovy, Zepbound, and Ozempic before you decide anything. Not available for Medicare, Medicaid, or TRICARE.

Prefer a members-pricing route or want to compare providers? Sesame Care offers a provider-choice route and Costco-member self-pay pricing on FDA-approved options like Wegovy and Ozempic — a reasonable second stop if Ro isn’t your fit. Check current pricing before you buy. Also see our full best brand-name GLP-1 providers comparison.

A quick word on insurance

Coverage is uneven, and it’s been shrinking. As of January 2026, KFF reported that 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service — down from 16 the year before — and usually only with prior authorization. We track this state by state in our Medicaid GLP-1 coverage tracker.

Medicare angle: a temporary program called the Medicare GLP-1 Bridge covers Wegovy and Zepbound for eligible Medicare Part D members at a $50 copay, and eligible members may also get Foundayo for about $50 a month starting July 1, 2026. That’s a separate, eligibility-based program — not the regular cash price — and a longer-term Medicare model is set to follow in 2027.

What should you do if your compounded GLP-1 just got canceled?

Safety note first: don’t stop, restart, ration, or change your dose on your own. This is about what to ask next, not a dosing plan.

Don’t panic-buy from a research-peptide site or an unverified online pharmacy — that’s how people end up with the salt forms, fake labels, and dosing errors the FDA warns about. Instead, take four calm steps.

Step 1: Get your records

Before you do anything else, write down (or ask your provider for): the exact medication name, the dose in milligrams, the concentration, the pharmacy's name, your prescriber's name, the date of your last dose, and any side effects you've had. You'll need this for whoever you talk to next.

Step 2: Ask why it stopped

"Was my refill stopped because of the FDA compounding rules, a pharmacy policy, a state law, my eligibility, or a supply issue -- and is there anything I can do?"

Step 3: Ask whether a legal version fits you

"Is there a documented, patient-specific medical reason a compounded version is necessary for me? Or should I move to an FDA-approved option?"

Step 4: Compare your options

Use the pricing table above, check your insurance, and pick the path that fits your budget and your health. If you're not sure where to start, that's exactly what our quiz is for.

Get your personalized GLP-1 transition plan in 60 seconds →

Answer a few quick questions and walk away with a checklist you can hand straight to your prescriber. No pressure, no sales pitch — just clarity.

How can you tell if a GLP-1 provider is actually legit?

A polished website, a low price, and the words “doctor-prescribed” don’t prove a provider is safe or legal. A trustworthy provider will clearly tell you who the prescriber is, which licensed pharmacy is involved, whether you’re getting an FDA-approved or compounded product, your dosing instructions, and what happens if the rules change. If a provider dodges those questions, treat that as your answer.

The RX Index legitimacy checklist

✓Is there a clearly named, licensed prescriber?
✓Is the pharmacy named before you pay, or at least before it ships?
✓Is it clear whether the medication is FDA-approved or compounded?
✓For compounded products, can they say it's 503A patient-specific -- and what reason is documented?
✓Do they avoid "generic Ozempic," "same as Wegovy," or "FDA-approved compound" language?
✓No "semaglutide sodium" or "semaglutide acetate"?
✓No retatrutide or cagrilintide?
✓Are the dosing instructions clear, in both milligrams and units?
✓Are shipping and refrigeration handled and explained?
✓Are the cancellation and refund terms clear?
✓Does the pharmacy name on the label match the pharmacy that actually filled it?

A good provider passes this list easily. A risky one starts getting vague. That difference is worth more than any discount.

Frequently asked questions

Are compounded GLP-1s banned after the shortage ended?: Not entirely. The broad shortage-based pathway for mass-market copies of semaglutide and tirzepatide has ended, but a narrow, patient-specific kind of compounding can still be legal when a prescriber documents a real medical reason.
Is compounded semaglutide still legal in 2026?: It depends on the facts -- the prescription, the pharmacy, the formula, and whether there's a documented patient-specific reason. Routine, mass-market copies should not be treated the way they were during the shortage.
Is compounded tirzepatide still legal in 2026?: Same framework as semaglutide. The shortage-based window closed in 2025, and any ongoing compounding needs a genuine, documented, individual reason -- not a marketing claim.
Can pharmacies still compound GLP-1s if they add B12?: Adding B12 does not automatically make a copy legal. The FDA has said a semaglutide-plus-B12 product can still count as essentially a copy depending on the dose and route. Ask what specific medical difference was documented for you.
What is 503A compounding?: 503A refers to a state-licensed pharmacy (or physician) compounding a medication for one named patient based on a prescription.
What is 503B compounding?: 503B refers to larger outsourcing facilities that make compounded drugs in batches under stricter federal rules, with tight limits on using raw drug powder unless the drug is in shortage or on a special approved-ingredient list.
Are compounded GLP-1s FDA-approved?: No. The FDA does not review compounded drugs for safety, effectiveness, or quality before they're sold, and they are not the same as FDA-approved generics.
What should I do if my refill was canceled?: Don't buy from an unverified seller. Get your prescription records, ask your provider why it stopped, ask whether a legal option fits you, and compare FDA-approved programs before you spend anything.
Are semaglutide sodium and semaglutide acetate safe?: The FDA says these salt forms are different active ingredients than the approved drug and that it is aware of no lawful basis for using them in compounding. Treat them as a red flag.
Can I just buy retatrutide or cagrilintide online instead?: No. The FDA says these cannot legally be compounded and have not been found safe or effective for any condition. Don't buy them from research-peptide sellers.
Why are some providers still advertising compounded GLP-1s?: Some lean on patient-specific compounding arguments, different formulas, or outdated marketing. Verify the prescriber, the pharmacy, and the legal basis before trusting any of it.
What's the best legal option now that compounded access has changed?: For most people, the most straightforward legal path is an FDA-approved medication prescribed by a licensed clinician -- but your eligibility, cost, coverage, diagnosis, and medical history decide what's right for you.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz. You’ll get a plain-English, next-step checklist based on your medication, your insurance status, your budget, and whether your current refill is still available — something you can bring straight to your prescriber.

Take the free 60-second matching quiz →Or check your FDA-approved coverage now — free with Ro →

For clinics and weight-loss practices: the same FDA rules point in one direction — the routine-compounding model for semaglutide and tirzepatide is effectively over. Plan FDA-approved transitions for your patients, and treat any “significant difference” compounding as genuinely individualized and documented, not a template. The April 2026 proposal to exclude these drugs from bulk compounding signals the rules are only tightening.

Disclosure

The RX Index may earn a commission if you use some links on this page. That never changes the FDA facts, the sources we cite, or our advice to confirm any medication with a licensed clinician.

What we actually verified for this page

We reviewed the FDA’s own statements on GLP-1 compounding policy, the shortage-resolution dates and the court decisions that set the enforcement deadlines, the FDA’s safety concerns about unapproved GLP-1 drugs, the FDA’s March 2026 telehealth warning-letter announcement, the April 2026 proposed rule on bulk compounding, KFF’s January 2026 Medicaid coverage data, and current public self-pay pricing from manufacturer programs and Ro. Pricing and provider details were last checked on June 9, 2026 — re-confirm any price before you make a decision.